Compare Stocks: MNKD, ACAD, DYN, and EWTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.50 +1.6%	$25.96	$19.69 ▼ $30.96	$5.08B	0.81	1.80 million shs	1.09 million shs
DYN Dyne Therapeutics	$26.10 +0.5%	$23.68	$11.92 ▼ $27.31	$4.87B	1.07	2.17 million shs	1.18 million shs
EWTX Edgewise Therapeutics	$44.18 +2.1%	$41.15	$13.69 ▼ $48.40	$4.80B	0.3	1.35 million shs	1.25 million shs
MNKD MannKind	$4.15 -2.6%	$4.03	$2.23 ▼ $6.51	$1.33B	1.12	4.99 million shs	3.20 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.46%	+18.81%	+39.81%	+18.28%
DYN Dyne Therapeutics	0.00%	+1.56%	+9.25%	+50.26%	+118.05%
EWTX Edgewise Therapeutics	0.00%	+0.02%	+12.45%	+35.11%	+219.22%
MNKD MannKind	0.00%	+7.79%	+6.68%	+22.78%	+4.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.50 +1.6%	$25.96	$19.69 ▼ $30.96	$5.08B	0.81	1.80 million shs	1.09 million shs
DYN Dyne Therapeutics	$26.10 +0.5%	$23.68	$11.92 ▼ $27.31	$4.87B	1.07	2.17 million shs	1.18 million shs
EWTX Edgewise Therapeutics	$44.18 +2.1%	$41.15	$13.69 ▼ $48.40	$4.80B	0.3	1.35 million shs	1.25 million shs
MNKD MannKind	$4.15 -2.6%	$4.03	$2.23 ▼ $6.51	$1.33B	1.12	4.99 million shs	3.20 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+4.46%	+18.81%	+39.81%	+18.28%
DYN Dyne Therapeutics	0.00%	+1.56%	+9.25%	+50.26%	+118.05%
EWTX Edgewise Therapeutics	0.00%	+0.02%	+12.45%	+35.11%	+219.22%
MNKD MannKind	0.00%	+7.79%	+6.68%	+22.78%	+4.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$34.19	15.91% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	31.86% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	13.93% Upside
MNKD MannKind	2.60	Moderate Buy	$9.22	122.14% Upside

Current Analyst Ratings Breakdown

Latest MNKD, ACAD, DYN, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/11/2026	EWTX Edgewise Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$32.00 ➝ $36.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$14.00 ➝ $13.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.74	$0.89 per share	33.25	$7.58 per share	3.89
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.13 per share	N/A
MNKD MannKind	$393.63M	3.39	$0.06 per share	67.07	($0.21) per share	-19.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.29	31.05	23.23	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)

Latest MNKD, ACAD, DYN, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
DYN Dyne Therapeutics	0.28	12.02	12.02
EWTX Edgewise Therapeutics	N/A	16.24	16.24
MNKD MannKind	N/A	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
DYN Dyne Therapeutics	96.68%
EWTX Edgewise Therapeutics	N/A
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
DYN Dyne Therapeutics	9.46%
EWTX Edgewise Therapeutics	21.30%
MNKD MannKind	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
EWTX Edgewise Therapeutics	60	108.60 million	85.47 million	Optionable
MNKD MannKind	400	321.54 million	313.18 million	Optionable

MNKD, ACAD, DYN, and EWTX Headlines

Recent News About These Companies

MannKind Corporation (NASDAQ:MNKD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 23 at 2:29 AM | americanbankingnews.com

MannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Moderate Buy" from Analysts

August 23 at 2:28 AM | marketbeat.com

MannKind (NASDAQ:MNKD) Shares Cross Above Two Hundred Day Moving Average - Here's Why

August 22 at 2:41 AM | americanbankingnews.com

MannKind (NASDAQ:MNKD) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?

August 22 at 2:39 AM | marketbeat.com

MannKind Prepares Shelf Registration for Potential Stock Offering

August 21 at 4:31 PM | tipranks.com

HC Wainwright Issues Negative Estimate for MannKind Earnings

August 15, 2026 | americanbankingnews.com

Research Analysts Set Expectations for MannKind Q3 Earnings

August 14, 2026 | marketbeat.com

MannKind FY2029 EPS Estimate Decreased by HC Wainwright

August 13, 2026 | marketbeat.com

MannKind: New Approvals Majorly Increase MannKind's Prospects

August 13, 2026 | seekingalpha.com

MannKind: New Approvals Majorly Increase MannKind's Prospects

August 13, 2026 | seekingalpha.com

Mannkind Corp

August 12, 2026 | money.usnews.com

Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock

August 10, 2026 | marketbeat.com

Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD

August 10, 2026 | marketbeat.com

First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD

August 9, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD

August 9, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)

August 7, 2026 | theglobeandmail.com

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)

August 7, 2026 | theglobeandmail.com

MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating

August 7, 2026 | marketbeat.com

Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD

August 7, 2026 | marketbeat.com

MannKind outlines $110M-$120M 2026 Furoscix revenue target as ReadyFlow ships in weeks

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MNKD, ACAD, DYN, and EWTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.50 +0.46 (+1.58%)

As of 08/21/2026 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Dyne Therapeutics NASDAQ:DYN

$26.10 +0.12 (+0.46%)

As of 08/21/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Edgewise Therapeutics NASDAQ:EWTX

$44.18 +0.89 (+2.06%)

As of 08/21/2026 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

MannKind NASDAQ:MNKD

$4.15 -0.11 (-2.58%)

As of 08/21/2026 04:00 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, ACAD, DYN, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, ACAD, DYN, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, ACAD, DYN, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNKD, ACAD, DYN, and EWTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Edgewise Therapeutics NASDAQ:EWTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNKD, ACAD, DYN, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNKD, ACAD, DYN, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNKD, ACAD, DYN, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNKD, ACAD, DYN, and EWTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Edgewise Therapeutics NASDAQ:EWTX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools